Merck Announces Management Changes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Merck Announces Management Changes



Merck KGaA reported the promotion of three internal managers to head the life-science-tools and consumer health divisions as well as its allergy business unit as part of its “Fit for 2018” program.

Udit Batra, who previously managed Consumer Health, will become president and CEO of the Life Science Tools division, succeeding Robert Yates, who has left the company. Uta Kemmerich-Keil, currently CEO of Allergopharma and head of the global allergy business unit, will succeed Batra in his role as president and CEO of Consumer Health. Kemmerich-Keil will be replaced at Allergopharma by Marco Linari, who was head of the Operating Model within Merck Millipore and Performance Materials. All changes will take effect May 15.

In addition, Merck Serono President and CEO Belén Garijo will take charge of the R&D organization ad interim while the search for a permanent leader for the R&D organization is conducted. Annalisa Jenkins, who served in that role, left the company at the end of March.

Source: Merck KGaA

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here